Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,004 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-Fluorouracil (5FU) Clear all
Completed Phase 1 Interventional

Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases

NCT00557557
View directory record Official record
Conditions
Colorectal Liver Metastases
Interventions
Drug: 5-FU, Drug: Oxaliplatin
Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer

NCT00001239
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
FLAC with GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Results available

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

NCT03250832
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 15, 2026, 1:14 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

NCT04642287
View directory record Official record
Conditions
Immunotherapy, Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Organ Transplant Recipients, Skin Cancer
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 15, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

NCT04757363
View directory record Official record
Conditions
Esophagogastric Cancer, HER2-Negative
Interventions
regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

NCT01611857
View directory record Official record
Conditions
Malignant Solid Tumour, Gastroesophageal Cancer
Interventions
Tivantinib, FOLFOX
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
New Haven, Connecticut • Fort Myers, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 15, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211
View directory record Official record
Conditions
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Interventions
Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

NCT03699319
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
Drug
Lead sponsor
David Bajor, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 15, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional

Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer

NCT00006037
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, irinotecan hydrochloride, oglufanide disodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 15, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

NCT02688712
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
LY2157299, Capecitabine, Fluorouracil, Tumor specific mesorectal excision
Drug · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322
View directory record Official record
Conditions
Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
Interventions
Bevacizumab, FOLFIRI, Pelareorep
Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Homewood, Alabama • Beverly Hills, California • Encino, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Results available

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

NCT02508077
View directory record Official record
Conditions
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Panitumumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Duarte, California • Lancaster, California • Rancho Cucamonga, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Early Phase 1 Interventional

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

NCT01821612
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids

NCT04710719
View directory record Official record
Conditions
Keloid, Keloid Scar Following Surgery
Interventions
Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil injection
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 15, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

NCT04141995
View directory record Official record
Conditions
Pancreas Cancer, Adenocarcinoma of the Pancreas
Interventions
Digoxin, 5Fluorouracil, Calcium Leucovorin, Irinotecan, Oxaliplatin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

NCT00468169
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, 5-FU, Hydroxyurea, Twice-daily radiation, Cisplatin, Accelerated fraction radiotherapy with concomitant boost
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 15, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

NCT04643366
View directory record Official record
Conditions
Rectal Cancer
Interventions
Chemotherapy, Radiation Therapy
Drug · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
4
States / cities
Richmond, Virginia • South Hill, Virginia • Tappahannock, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

NCT00981656
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, 5-fluorouracil, Mitomycin, Three-Dimensional Conformal Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
13
States / cities
Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

NCT07340151
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Surgical resection
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 15, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

NCT07603375
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 1:14 AM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

NCT00368329
View directory record Official record
Conditions
Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
Interventions
Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU), Carboplatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 15, 2026, 1:14 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx

NCT00004164
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, cisplatin, docetaxel, fluorouracil, leucovorin calcium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 15, 2026, 1:14 AM EDT
Withdrawn Not applicable Interventional

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

NCT00814528
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-ALA plus Blu-Light, 5-FU, Imiquimod or treatment with cryotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 15, 2026, 1:14 AM EDT
Terminated Phase 3 Interventional Results available

Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed

NCT00002525
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2015
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 15, 2026, 1:14 AM EDT